BackEndonovo Therapeutics Overview

Endonovo Therapeutics Current Assets

Track Endonovo Therapeutics's current assets ($43K) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Current Assets
$43271.00
↑ 141.12% YoYΔ $25325.00 vs prior year quarter

Peer trimmed avg / median

Loading

Endonovo Therapeutics Current Assets History

Loading

Endonovo Therapeutics vs. peers: Current Assets Comparison

Loading

Endonovo Therapeutics Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Endonovo Therapeutics (ENDV) FAQ

Endonovo Therapeutics's current assets stands at $43K as of June 2026. That compares with $18K in the prior-year period — up 141.1% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Endonovo Therapeutics reported $43K in current assets versus $18K a year earlier — a 141.1% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $18K in the prior-year period — up 141.1% year over year. Sustained growth in current assets can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Endonovo Therapeutics's current assets evolved across reporting periods, while the comparison chart places ENDV next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, current assets is commonly used to spot outliers. Endonovo Therapeutics's reading of $43K is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.